Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430857 | 1.00 | CYP1A2 (0.50) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL27304077 | 1.00 | CYP1A2 (0.50) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL11443780 | 0.85 | CYP1A2 (0.55) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL7019012 | 0.84 | CYP1A2 (0.47) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL22483309 | 0.84 | CYP1A2 (0.47) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL29025957 | 0.81 | CYP1A2 (0.52) | CYP1A2CA2 | |
| SCHEMBL19417348 | 0.81 | CYP1A2 (0.52) | CYP1A2CA2 | |
| SCHEMBL1992348 | 0.80 | PTGS1 (0.46) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL19478896 | 0.80 | CYP1A2 (0.47) | CYP1A2PTGS1AHRFBP1NQO2 | |
| SCHEMBL22931544 | 0.79 | AHR (0.68) | CYP1A2PTGS1AHRFBP1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112266352-B | Piperlongumine derivative and preparation method and application thereof | 绍兴文理学院 | 2022-02-08 | — | — | CN | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2012028578-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-8110684-B2 | Diaza-spiro [4.5] decanes useful as pesticides | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110684-B2 | Diaza-spiro [4.5] decanes useful as pesticides | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100227862-A1 | DIAZA-SPIRO [4.5] DECANES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP1A2 420/4885PTGS1 2872/4885AHR 1050/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | CYP1A2 2930/4885PTGS1 1974/4885AHR 3797/4885 |
| US-20100227862-A1 | DIAZA-SPIRO [4.5] DECANES USEFUL AS PESTICIDES | DDT, CHRM1, DECR1 | CYP1A2 925/4885PTGS1 2483/4885AHR 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.